Related Experiment Video
Updated: Aug 6, 2026
Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model
Published on: April 18, 2015
Prospective comparison of [68Ga]Ga-FAPI-04 PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI for predicting
Yuming Luo1, Xiao Zhang2,3,4, Runze Li1
1Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China.
Purpose:
Accurate assessment of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) remains challenging in breast cancer. This prospective single-center study compared [68Ga]Ga-FAPI-04 PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI for predicting pathologic response after NAC.
Methods:
Women with biopsy-confirmed stage II-III breast cancer underwent baseline and post-therapy [68Ga]Ga-FAPI-04 PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI before surgery. PET parameters were analyzed for primary tumors and axillary nodes. Selected variables were evaluated using LASSO and receiver-operating-characteristic analyses. Stromal FAP expression was assessed immunohistochemically in paired specimens.
Results:
Twenty-four patients completed the protocol, yielding 25 primary lesions and 44 metastatic lymph nodes across 27 axillary compartments. The pCR rate was 60.00% for primary lesions and 72.73% for axillary nodes. For primary-lesion response, post-therapy [68Ga]Ga-FAPI-04 SUVmax showed the highest performance (AUC, 0.84; sensitivity, specificity, and accuracy, 80.00% each); the best [18F]FDG parameter was ΔTBR% (AUC, 0.747). For nodal response, post-therapy [68Ga]Ga-FAPI-04 SULmean showed the highest performance (AUC, 0.89; sensitivity, 91.67%; specificity, 81.25%; accuracy, 84.09%) and exceeded the best [18F]FDG parameter on DeLong testing. MRI AUCs were 0.733 and 0.770 for primary and nodal disease, respectively. Stromal FAP expression correlated positively with [68Ga]Ga-FAPI-04 SUVmax.
Conclusion:
Post-therapy [68Ga]Ga-FAPI-04 PET may provide useful adjunctive information for response assessment after NAC in breast cancer, particularly for axillary nodal evaluation, potentially supporting more individualized preoperative planning.
Trial Registration:
ClinicalTrials.gov, NCT07553741, retrospectively registered.
